

5. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: Recognition and prevention strategies. *Crit Care Med* 2010; 38(6 Suppl): S169–S174
6. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. *Nat. Rev. Nephrol.* 2010, 6, 461–470. [Google Scholar] [CrossRef] [PubMed]
7. Mulligan MJ, Cobbs CG. Bacteriostatic versus bactericidal activity. *Infect Dis Clin North Am.* 1989 Sep;3(3):389-98. PMID: 2671128.
8. Norrby SR. Neurotoxicity of carbapenem antibacterials. *Drug Saf.* 1996 Aug;15(2):87-90. doi: 10.2165/00002018-199615020-00001. PMID: 8884160.
9. Krause KM, Serio AW, Kane TR et al. Aminoglycosides: An Overview. *Cold Spring Harb Perspect Med.* 2016 Jun 1;6(6):a027029. doi: 10.1101/cshperspect.a027029. PMID: 27252397; PMCID: PMC4888811.
10. Drew R. Aminoglycosides, doi: <https://www.uptodate.com/contents/aminoglycosides?c=caef2e4f-8240-441a-9b16-ad0d8542df77&source=contentShare>
11. Humes HD. Aminoglycoside nephrotoxicity. *Kidney Int* 1988; 33:900.
12. McWilliam SJ, Antoine DJ, Smyth RL, et al. Aminoglycoside-induced nephrotoxicity in children. *Pediatr Nephrol.* 2017;32:2015-25.
13. Denamur S, Boland L, Beyaert M et al. Subcellular mechanisms involved in apoptosis induced by aminoglycoside antibiotics: Insights on p53, proteasome and endoplasmic reticulum. *Toxicol Appl Pharmacol.* 2016;309:24-36.
14. Martínez-Salgado C, Rodríguez-Barbero A, Eleno N et al. Gentamicin induces Jun-AP1 expression and JNK activation in renal glomeruli and cultured mesangial cells. *Life Sci.* 2005;77:2285-98.
15. Drew R, Sakoulas G. Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults, doi: <https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults?csi=aaaf3a27-9cc2-461e-9987-b7c4170e7c41&source=contentShare>
16. Elyasi S, Khalili H, Dashti-Khavidaki S et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. *Eur J Clin Pharmacol.* 2012;68:1243-55.
17. Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. *Clin J Am Soc Nephrol.* 2016 Dec 7;11(12):2132-2140. doi: 10.2215/CJN.05920616. Epub 2016 Nov 28. PMID: 27895134; PMCID: PMC5142072.
18. Sawada A, Kawanishi K, Morikawa S et al. Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review. *BMC Nephrol.* 2018 Mar 27;19(1):72. doi: 10.1186/s12882-018-0845-1. PMID: 29587650; PMCID: PMC5872390.
19. Petejova N, Martinek A, Zahalkova J et al. Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2012 Dec;156(4):342-7. doi: 10.5507/bp.2012.002. Epub 2012 Jan 30. PMID: 22660225.
20. Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. *Expert Rev Anti Infect Ther.* 2015;13(12):1481-97. doi: 10.1586/14787210.2015.1093933. Epub 2015 Oct 21. PMID: 26488563.
21. MacLaren G, Spelman D. Polymyxins: An overview, doi: <https://www.uptodate.com/contents/polymyxins-an-overview?csi=119451e1-13c2-436d-810c-7ec1fdfad5f1&source=contentShare>
22. Lima LM, Silva BNMD, Barbosa G et al.  $\beta$ -lactam antibiotics: An overview from a medicinal chemistry perspective. *Eur J Med Chem.* 2020 Dec 15;208:112829. doi: 10.1016/j.ejmech.2020.112829. Epub 2020 Sep 16. PMID: 33002736.
23. González E, Gutiérrez E, Galeano C et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. *Kidney Int.* 2008;73:940-6.
24. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. *Pharmacotherapy.* 2014;34:670-6.
25. Gomes DM, Smotherman C, Birch A et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. *Pharmacotherapy.* 2014;34:662-9.
26. Navalkele B, Pogue JM, Karino S et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. *Clin Infect, Dis.* 2017;64:116- 23.
27. Mansoor GA, Panner BJ, Ornt DB. Azithromycin-induced acute interstitial nephritis. *Ann Intern Med* 1993;119:636-7.
28. Persico C, Rocchi A, Edefonti A et al. The acute interstitial nephritis induced by azithromycin. *NDT Plus.* 2011;4:218.
29. Woodruff AE, Meaney CJ, Hansen EA et al. Azithromycin-Induced, Biopsy-Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low-Dose Corticosteroids. *Pharmacotherapy.* 2015;35:e169-74.
30. Russell W, Smith W. Clarithromycin-induced acute interstitial nephritis and minimal change disease. *NDT Plus.* 2009;2:382-3.
31. Gandhi S, Fleet JL, Bailey DG et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. *JAMA.* 2013;310:2544-53.
32. Mishima E, Maruyama K, Nakazawa T et al. Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. *Intern Med.* 2017;56:1687-90
33. Drlca K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol Mol Biol Rev.* 1997 Sep;61(3):377-92. doi: 10.1128/mmr.61.3.377-392.1997. PMID: 9293187; PMCID: PMC232616.
34. Bolon B. Mini-Review: Toxic Tendinopathy. *Toxicol Pathol.* 2017 Oct;45(7):834-837. doi: 10.1177/0192623317711614. Epub 2017 May 28. PMID: 28553748.
35. Bird ST, Etminan M, Brophy JM, et al. Risk of acute kidney injury associated with the use of fluoroquinolones. *CMAJ.* 2013;185:E475-82.
36. Muriithi AK, Leung N, Valeri AM et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. *Am J Kidney, Dis.* 2014;64:558-66.
37. Khan M, Ortega LM, Bagwan N et al. Crystal-induced acute kidney injury due to ciprofloxacin. *J Nephropathol.* 2015;4:29-31.
38. Li Y, Zhu Y, Zhong Q et al. Serious Adverse Reactions From Anti-tuberculosis Drugs Among 599 Children Hospitalized for Tuberculosis. *Pediatr Infect Dis J.* 2017;36:720-5.
39. Wortham JM, Goggin M, Mora C et al. Acute kidney injury during treatment for latent tuberculous infection with rifampin. *Int J Tuberc Lung, Dis.* 2017;21:596-7.
40. Chang CH, Chen YF, Wu VC et al. Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population. *BMC Infect, Dis.* 2014;14:23.
41. Drew R, Sterling T. Antituberculous drugs: An overview, doi: [https://www.uptodate.com/contents/antituberculous-drugs-an-overview?search=antimycobacterials&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/antituberculous-drugs-an-overview?search=antimycobacterials&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
42. Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18. PMID: 28101605.